IDH2 and central nervous system neoplasm: The World Health Organization (WHO) in 2016 for the first time considered molecular parameters in addition to the histology for the CNS tumor classification and incorporated new entities that are defined both by the histology and molecular features, including GBM, IDH-wildtype, GBM, IDH-mutant along with other classes [3].